ANA PAULA BELTRAN MOSCHIONE CASTRO

(Fonte: Lattes)
Índice h a partir de 2011
10
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 8 Citação(ões) na Scopus
    Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
    (2021) DELEURAN, Mette; MARCOUX, Danielle; BRUIN-WELLER, Marjolein S. De; IRVINE, Alan D.; BASELGA, Eulalia; AHN, Kangmo; CASTRO, Ana Paula; BANSAL, Ashish; CHAO, Jingdong; BAGOUSSE, Gaelle Bego-Le; ROSSI, Ana B.
  • article 21 Citação(ões) na Scopus
    Current Progress and Future Perspectives on the Use of Bacillus clausii
    (2022) GHELARDI, Emilia; ABREU, Ana Teresa Abreu y; MARZET, Christian Boggio; CALATAYUD, Guillermo Alvarez; III, Marcos Perez; CASTRO, Ana Paula Moschione
    Bacillus clausii is a probiotic that benefits human health. Its key characteristics include the ability to form spores; the resulting tolerance to heat, acid, and salt ensures safe passage through the human gastrointestinal tract with no loss of cells. Although B. clausii has been widely used for many decades, the beneficial properties of other probiotics, such as Lactobacillus spp. and Bifidobacterium spp., are better disseminated in the literature. In this review, we summarize the physiological, antimicrobial, and immunomodulatory properties of probiotic B. clausii strains. We also describe findings from studies that have investigated B. clausii probiotics from the perspective of quality and safety. We highlight innovative properties based on biochemical investigations of non-probiotic strains of B. clausii, revealing that B. clausii may have further health benefits in other therapeutic areas.